Kuros Biosciences will hold its Capital Markets Day in Zürich on Wednesday, June 17, 2026, to present the commercial momentum of its MagnetOs bone graft and outline plans for scalable quality growth. The event will feature presentations on the company's global commercial strategy, including the continued expansion of MagnetOs across spine and foot and ankle markets and its entry into the trauma market, which represents an important new frontier for bone healing after acute injury. Kuros will also discuss its evidence generation efforts, highlighting a unique surgical exploration and biopsy initiative and progress in ongoing Level I human clinical trials, as well as new product development initiatives. UK orthopedic surgeon Mr. Andy Goldberg OBE will provide clinical perspectives, and a MagnetOs patient will share a personal recovery story. CEO Chris Fair stated that the company is focused on turning commercial momentum into durable scale, leveraging its evidence base, surgeon engagement, product pipeline, and expanding commercial infrastructure to support long-term value creation.
Kuros Biosciences AGCompany presents commercial momentum of MagnetOs and entry into trauma market, indicating growing end-customer demand.